The Cooper Companies, Inc. COO

NASDAQ · Healthcare · Medical - Instruments & Supplies

$58.88

Close on Fri, 20 Nov 2026 · market value $11.2B

What the price is betting on

Below its record

At $59, the price assumes revenue grows about 1% a year for five years, from $4.2B to about $4.4B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes1%
Analysts, next two years3.8%
Last 3 years6.2%

Revenue growth a year. The price figure comes from a reverse DCF at a 8.4% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than COO? Check up to 5 of your stocks at once, free, no account.

0$2B$4B$6B$4.2B'22'23'24'25Jul '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$62

Base

$69

Bull

$77

Today $59

  • Bear $62. Cash flow grows 2% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $69. Cash flow grows 4% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $77. Cash flow grows 6% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$4.2B$4.2B, on the path
  3. FY2027$4.3B$4.4B, on the path
  4. FY2028$4.3B$4.6B, on the path
  5. FY2029$4.4B$4.9B, on the path
  6. FY2030$4.4B$5.2B, on the path

Each year's revenue at 1% growth from $4.2B in the 12 months to July 2026.

At a glance

Healthcare · Medical - Instruments & Supplies · listed on NASDAQ

Revenue, FY2025
$4.1B
Growth, 3 years a year
6.2%
Cash margin
11%
Net debt
$2.7B
Shares, 3-year change
+0.6%
Dividend yield
0%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.